LISTING OF THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-24 (Canceled)

Please add the following new claims:

25. (New) A crystalline form 1 of bilastine having, upon X-ray crystallography analysis, crystal parameters of substantially the following:

Crystallographic system	Monoclinic	
Spatial group	P2 (1)/c	
Crystal size	0.56 x 0.45 x 0.24 mm	
Cell dimension	a=23.38 (5) A angstrom	$\alpha = 90°$
	b=8.829 (17) A	$\beta = 90°$
	c=12.59 (2) A	$\gamma = 90°$
Volume	2600 A^3	
Z, calculated density	4, 1.184 mg/m^3	

, an infrared spectrum in potassium bromide with the following bands:

Wavenumber (cm^{-1})

3057

2929

2883

2857

2797

1666

1481

1431

1346

1326

1288
1020
973
945
829

and an infrared spectrum in potassium bromide which is substantially identical to that shown in Figure 1.

26. (New) A process for preparing the crystalline form 1 of bilastine according to claim 25, wherein said process comprises heating bilastine in a solvent selected from the group consisting of short chain alcohols, acetone and mixtures thereof to a reflux temperature of the solvent.

27. (New) A process for preparing the crystalline form 1 of bilastine according to claim 25, wherein said process comprises heating crystalline forms 2 and 3 of bilastine or a mixture thereof in a solvent selected from the group consisting of short chain alcohols, acetone and mixtures thereof to a reflux temperature of the solvent.

28. (New) A method for obtaining at least one of an histaminic and antiallergenic effect in a subject in need thereof, which method comprises administering to said subject a sufficient amount of the crystalline form 1 of bilastine according to claim 25 in a solid pharmaceutical preparation to produce said effect.

29. (New) A solid pharmaceutical preparation comprising an effective amount of crystalline form 1 of bilastine according to claim 25 and a pharmaceutically acceptable solid excipient.

30. (New) A method for forming a solid pharmaceutical preparation which comprises incorporating within said preparation an amount of crystalline form 1 of bilastine according to claim 25 effective to treat allergic reactions and pathological processes mediated by histamine.

31. (New) The process of claim 26, wherein the short chain alcohol is isopropylic alcohol or n-butanol.

32. (New) The process of claim 27, wherein the short chain alcohol is isopropylic alcohol or n-butanol.